On May 2, 2024, Allarity Therapeutics, Inc. announced the early conclusion of its Phase 2 clinical trial for stenoparib, a novel PARP inhibitor aimed at treating advanced recurrent ovarian cancer. The decision to end the trial ahead of schedule was based on the significant clinical benefits observed, including tumor shrinkage and long-term disease stability in heavily pre-treated patients. These promising results have provided sufficient proof of concept for stenoparib as a monotherapy, leading Allarity to focus on developing a follow-on trial with the intent of regulatory submission. The trial utilized Allarity's proprietary Drug Response Predictor (DRP®) companion diagnostic to pre-screen patients, ensuring that only those with the highest likelihood of benefit were treated. The company plans to rapidly analyze the trial data and present a more comprehensive update as soon as possible. The early trial conclusion is a significant milestone for Allarity, reflecting its commitment to addressing the urgent needs of advanced ovarian cancer patients.

On May 2, 2024, Allarity Therapeutics, Inc. announced the early conclusion of its Phase 2 clinical trial for stenoparib, a novel PARP inhibitor aimed at treating advanced recurrent ovarian cancer. The decision to end the trial ahead of schedule was based on the significant clinical benefits observed, including tumor shrinkage and long-term disease stability in heavily pre-treated patients. These promising results have provided sufficient proof of concept for stenoparib as a monotherapy, leading Allarity to focus on developing a follow-on trial with the intent of regulatory submission. The trial utilized Allarity's proprietary Drug Response Predictor (DRP®) companion diagnostic to pre-screen patients, ensuring that only those with the highest likelihood of benefit were treated. The company plans to rapidly analyze the trial data and present a more comprehensive update as soon as possible. The early trial conclusion is a significant milestone for Allarity, reflecting its commitment to addressing the urgent needs of advanced ovarian cancer patients.